SCHEDULE: Janus Henderson Discloses 9.99% Stake in IMMUNIC, INC.

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in IMMUNIC, INC., totaling 12,016,444 shares of common stock.

Summary

• Janus Henderson Group plc, a Jersey-based entity, has filed a Schedule 13G indicating beneficial ownership of 12,016,444 shares of common stock in IMMUNIC, INC.
• This ownership represents 9.99% of IMMUNIC, INC.'s outstanding common stock.
• The reported shares include certain pre-funded and/or common warrants.
• An additional 13,327,439 Series A and 13,327,439 Series B common warrants are not included in the reported figures due to a beneficial ownership cap of 9.99% to prevent exceeding the threshold.
• Janus Henderson Group plc certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of IMMUNIC, INC.
• The filing was made under Rule 13d-1(b), classifying the investment as passive.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment regarding the issuer's performance or prospects. It simply reports a significant passive stake by an institutional investor.

Positives

• A significant institutional investor, Janus Henderson Group plc, has taken a substantial passive stake in IMMUNIC, INC., potentially signaling confidence in the company's long-term prospects.
• The investment is classified as passive, indicating no immediate intent to influence or change control of the issuer.

Negatives

• No specific negative information regarding IMMUNIC, INC. is disclosed in this ownership filing.

Risks

• No specific risks related to IMMUNIC, INC.'s operations or financial health are detailed in this Schedule 13G filing. The filing is solely for reporting beneficial ownership.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding IMMUNIC, INC.'s future performance or strategic outlook.

Management Comments

• No direct quotes or paraphrased statements from IMMUNIC, INC. management are included in this Schedule 13G filing.

Industry Context

This filing indicates a significant institutional investment in IMMUNIC, INC., which is common in the public markets as asset managers like Janus Henderson allocate capital across various sectors. The specific implications for IMMUNIC, INC. within its industry would depend on the company's sector and current market conditions, which are not detailed in this ownership disclosure.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership by a large institutional investor. It does not provide performance metrics or operational results for IMMUNIC, INC. that would allow for a comparison to industry standards or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: Existing shareholders may view the significant stake by Janus Henderson as a vote of confidence, potentially leading to increased investor interest.
• Management: The presence of a large, passive institutional investor may encourage management to maintain strong corporate governance and performance.

Next Steps

• No specific future actions, events, or milestones for IMMUNIC, INC. are mentioned in this beneficial ownership filing.

Key Dates

Keywords

IMMUNIC INC, Janus Henderson Group, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, equity holding, 4525EP101